Walleye Capital
NVS icon

Walleye Capital’s Novartis NVS Stock Holding History

Walleye Capital’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,734
Closed -$2.06M – 5052
2026
Q1 		$2.1M Buy
13,734
+13,733
+1,373,300% +$2.11M 0.01% 1426
2025
Q4 		$138 Sell
1
-20,854
-100% -$2.73M ﹤0.01% 4427
2025
Q3 		$2.67M Buy
20,855
+17,067
+451% +$2.08M 0.01% 1365
2025
Q2 		$458K Sell
3,788
-1,370
-27% -$154K ﹤0.01% 2716
2025
Q1 		$575K Buy
5,158
+5,038
+4,198% +$536K ﹤0.01% 2434
2024
Q4 		$11.7K Sell
120
-29,186
-100% -$3.11M ﹤0.01% 4568
2024
Q3 		$3.37M Buy
29,306
+25,743
+723% +$2.92M 0.01% 1478
2024
Q2 		$379K Sell
3,563
-10,735
-75% -$1.08M ﹤0.01% 3753
2024
Q1 		$1.38M Buy
+14,298
New +$1.47M ﹤0.01% 2278
2018
Q3 		$410K Buy
+5,307
New +$392K 0.19% 147

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Walleye Capital's NVS Position: Q2 2026 in Review

Walleye Capital sold out of Novartis (NVS) in Q2 2026, closing a stake of 13,734 shares — an estimated $2.06M sold.

Walleye Capital first reported a position in NVS in Q3 2018 and held it in 10 quarters. The position peaked at $3.37M in Q3 2024. 1,622 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Walleye Capital reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 13,734 Novartis shares in Q2 2026, an estimated $2.06M.
  • Walleye Capital first reported a position in Novartis in Q3 2018 and held it in 10 quarters.
  • Walleye Capital's Novartis position peaked at $3.37M in Q3 2024.
  • 1,622 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.